Results 111 to 120 of about 3,215 (175)

Reply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance. [PDF]

Hum Reprod Open
Chouchana L, Henry A, Bourdon M, Maignien C, Chapron C, Treluyer JM, Guibourdenche J, Santulli P.   +7 more
europepmc   +1 more source

Dydrogesterone for preventing endometrial polyp recurrence after transcervical resection of polyps: protocol for a multicentre randomised controlled trial in China. [PDF]

BMJ Open
Ge Y, Wang T, Qian L, Yan D, He Y, Ye L, Huang X.   +6 more
europepmc   +1 more source

Maternal serum progesterone and BMI are associated with neonatal sex ratios following single frozen embryo transfer. [PDF]

PLoS One
Czech R, Wójcik D, Skweres T, Śliwiński W, Zamkowska D, Ciepiela P.   +5 more
europepmc   +1 more source

The Clinical Implications of Progesterone in Preeclampsia. [PDF]

Biomolecules
Liu Z, Gu W.
europepmc   +1 more source

Gonadotropin-releasing hormone agonist (GnRH-a) pretreatment duration and letrozole supplementation for optimizing live birth rates in women with adenomyosis undergoing frozen-thawed embryo transfer (GOLD-FET): study protocol for a multicenter, 2 × 2 factorial randomized controlled trial in China. [PDF]

Trials
Xiong Y, Gu F, Du L, Gu J, Ke Z, Xu Y, Mol BW, Zheng B, Lin X, Xu Y.   +9 more
europepmc   +1 more source

Correction to: Birth defects reporting and the use of dydrogesterone: a disproportionality analysis from the World Health Organization pharmacovigilance database (VigiBase). [PDF]

Hum Reprod Open
europepmc   +1 more source

Comparison of oral dydrogesterone and vaginal progesterone for luteal phase support in natural and modified natural cycle frozen embryo transfers. [PDF]

J Ovarian Res
Xie YX, Jiang LL, Huang J, Li L, Qiu Q, Pan P, Li Y.   +6 more
europepmc   +1 more source

RETRACTION: <b>Comparison of the Effect of Dydrogesterone and Natural Micronized Progesterone for Luteal-Phase Support in Assisted Reproductive Technology Cycles: A Single-Blind Randomized Clinical Trial Study</b>. [PDF]

Health Sci Rep
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Selectivity and potency of the retroprogesterone dydrogesterone in vitro

Steroids, 2011
Dydrogesterone is widely used for menstrual disorders, endometriosis, threatened and habitual abortion and postmenopausal hormone replacement therapy. Although progestins have a promiscuous nature, dydrogesterone does not have clinically relevant androgenic, estrogenic, glucocorticoid or mineralocorticoid activities.
Tea Lanišnik Rižner, Bettina Husen, Edwin Sonneveld   +2 more
exaly   +3 more sources